Skip to main content
SpringerLink
Log in

Introduction to Pharmacodynamics

  • Chapter
  • First Online:
Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Abstract

Since the early appreciation of differences in the time course of antimicrobial activity, much has been learned about the pharmacodynamics of antimicrobials. Specific PK/PD indices have been identified which are of major importance for efficacy and for the prevention of the emergence of resistance. Of major importance, the magnitudes of these PK/PD indices for efficacy have been shown to be very similar in animal infection models and human infections. Modeling has also identified that there are few differences in the index magnitude with different dosing intervals, among drugs within the same antimicrobial class (providing free drug concentrations are used), with different infection sites (except occasionally for pneumonia), and among susceptible and resistant strains of the same type of bacteria. Addition studies have shown that the magnitude of indices can increase significantly with a higher inoculum for S. aureus and that neutrophils have a minor enhancing effect on antimicrobial activity against Enterobacteriaceae but a more variable enhancing effect on activity against S. pneumonia for different antimicrobials. Pharmacodynamic modeling has many applications including establishing new optimal dosing regimens, developing new antimicrobials and formulations, determining susceptibility breakpoints, providing guidelines for empiric therapy, and formulary development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ambrose PG, Bhavinani SM, Owen RC (2003) Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 17:529–543

    Article  PubMed  Google Scholar 

  • Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: not just for mice anymore. Clin Infect Dis 44:79–86

    Article  CAS  PubMed  Google Scholar 

  • Andes RD, Craig WA (1999) Pharmacodynamics of gemifloxacin (GEM) against quinolone-resistant strains of S. pneumoniae (SP) with known resistance mechanisms. In: Proceedings and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology, Washington, DC, Abstract 2032, p 50

    Google Scholar 

  • Andes D, Craig WA (2000) In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 44:1247–1254

    Article  Google Scholar 

  • Andes D, Craig WA (2002) Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261–268

    Article  CAS  PubMed  Google Scholar 

  • Andes D, Craig WA (2005a) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11(Suppl 6):10–17

    Article  PubMed  Google Scholar 

  • Andes D, Craig WA (2005b) Understanding pharmacokinetics and pharmacodynamics: application to the antimicrobial formulary decision process. In: Owen RC, Ambrose PG, Nightingale CH (eds) Antibiotic optimization: concepts and strategies in clinical practice. Dekker, New York, NY, pp 65–88

    Google Scholar 

  • ATS/IDSA Guideline Committee (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416

    Article  Google Scholar 

  • Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL (2010) Daptomycin exposure and probability of creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50:1568–1574

    Article  CAS  PubMed  Google Scholar 

  • Blondeau JM, Zhao X, Hansen G, Drlica K (2001) Mutation prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:433–438

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Brodey GP, Ketchel SJ, Rodriguez V (1979) A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 67:608–616

    Article  Google Scholar 

  • Bulik CC, Nicolau DP (2010) In vivo efficacy of simulated dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 54:4112–4115

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bundtzen REW, Gerber AU, Cohn DL, Craig WA (1981) Postantibiotic suppression of bacterial growth. Rev Infect Dis 3:28–37

    Article  CAS  PubMed  Google Scholar 

  • Cars O, Odenholt-Tornqvist I (1993) The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 31(Suppl D):159–166

    Article  CAS  PubMed  Google Scholar 

  • Christianson JC, Craig WA, Kiem S, Andes DR (2002) Impact of neutrophils on pharmacodynamic activity of clindamycin (CLINDA) and doxycycline (DOXY) against Streptococcus pneumoniae. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, Washington, DC, Abstract A-1267, p 15

    Google Scholar 

  • Craig WA (1995) Interrelationship of pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89–96

    Article  CAS  PubMed  Google Scholar 

  • Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of ß-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479–501

    Article  PubMed  Google Scholar 

  • Craig WA (2007) Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (eds) Antimicrobial pharmacodynamics in theory and clinical practice, 2nd edn. Informa Healthcare USA, New York, NY, pp 1–19

    Chapter  Google Scholar 

  • Craig WA, Andes D (1996) Pharmacokinetics and pharmacodynamics in otitis media. Pediatr Infect Dis J 15:255–259

    Article  CAS  PubMed  Google Scholar 

  • Craig WA, Andes DR (2000) Correlation of the magnitude of the AUC24/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model. Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, Washington, DC, Abstract 289, p 7

    Google Scholar 

  • Craig W, Andes D (2004) Activity of Oritavancin (O) versus Vancomycin (V) in the neutropenic murine thigh- and lung-infection models. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology, Washington, DC, Abstract A-1863, p 37

    Google Scholar 

  • Craig WA, Dalhoff A (1998) Pharmacodynamics of fluoroquinolones in experimental animals. In: Kuhlman J, Dalhoff A, Zeiler HJ (eds) Quinolone antibacterials, vol 127, Handbook of experimental pharmacology. Springer, Berlin, pp 207–232

    Chapter  Google Scholar 

  • Craig WA, Gudmundsson S (1996) Postantibiotic effect. In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams & Wilkins, Baltimore, MD, pp 296–329

    Google Scholar 

  • Craig WA, Ebert S, Leggett J, Redington J (1990) Effect of neutrophils on in vivo potency of antibiotics against Klebsiella pneumoniae. In: Program and abstracts of the 30th interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology, Washington, DC, Abstract 151, p 24

    Google Scholar 

  • Craig WA, Redington J, Ebert SC (1991) Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl C):29–40

    Article  CAS  PubMed  Google Scholar 

  • Craig WA, Ebert S, Watanabe Y (1993) Differences in time above MIC (T > MIC) required for efficacy of beta-lactams in animal model infections. In: Program and abstracts of the 33rd interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology, Washington, DC, Abstract 86, p 135

    Google Scholar 

  • Craig WA, Kethireddy S, Jones R, Stamstad T, Ashbeck J, Marchillo K, Andes DR (2008) Impact of KPCs on the in vivo activity of three carbapenems in the neutropenic mouse-thigh infection model. In: Abstracts of the 48th interscience conference on antimicrobial agents and chemotherapy and the infectious disease society if America 46th annual meeting, American Society of Microbiology, Washington, DC, Abstract A-029, p 8

    Google Scholar 

  • Crandon JL, Bulik CC, Nicolau DP (2009) In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:4352–4356

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cui X, Liu Y, Wang R, Tong W, Drlica K, Zhao X (2006) The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 194:1601–1608

    Article  PubMed  Google Scholar 

  • Drlica K (2003) The mutation selection window and antibiotic resistance. J Antimicrob Chemother 52:13–17

    Article  Google Scholar 

  • Eagle H, Fleishman R, Musselman AD (1950) Effect of schedule pf administration on the therapeutic efficacy of penicillin. Am J Med 9:280–299

    Article  CAS  PubMed  Google Scholar 

  • Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP (2009) In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther 31:2678–2688

    Article  CAS  PubMed  Google Scholar 

  • Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH (2006) Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58:1185–1192

    Article  CAS  PubMed  Google Scholar 

  • Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073–1081

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Garrod LP (1948) The bactericidal action of streptomycin. Br Med J 1:382–386

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gums JG (2003) NCCLS perspective in changing susceptibility breakpoints for antimicrobial drugs. Int J Antimicrob Agents 22(Supp 1):S3–S13

    Article  CAS  PubMed  Google Scholar 

  • Hughes DW, Frei CR, Maxwell PR, Green K, Patterson JE, Crawford GE, Lewis JS 2nd (2009) Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 53:2014–2019

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jacobs MR, Bajaksovzian S, Ziles A, Lin G, Pankuch GA, Appelbaum PC (1999) Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters. Antimicrob Agents Chemother 43:1901–1908

    CAS  PubMed Central  PubMed  Google Scholar 

  • Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhauet R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL (2003) Application of a mathematical model to prevent in vivo amplication of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112:275–285

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kahlmeter G (2008) Breakpoints for intravenously used cephalosporins in Enterobacteriaceae – EUCAST and CLSI breakpoints. Clin Microbiol Infect 14(Suppl 1):169–174

    Article  CAS  PubMed  Google Scholar 

  • Kashuba AD, Nafziger AN, Drusano GL, Bertino JS (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43:623–629

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kuller R, Davis SL, Levine DP, Rybak MJ (2011) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52:975–981

    Article  Google Scholar 

  • Kunin CM (1966) Clinical pharmacology of the new penicillins: I. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin Pharmacol Ther 7:166–179

    CAS  PubMed  Google Scholar 

  • Lee D, Murakami Y, Stamstad T, Marchillo J, Ashbeck J, Andes DR, Craig WA (2007) Inoculum effect of daptomycin, linezolid, vancomycin and ceftibiprole with Staphylococcus aureus and Streptococcus pneumoniae in neutropenic mice at 105 and 107 cfu in opposite thighs. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy, American Society of Microbiology, Washington, DC, Abstract A-37, 2007, p 9

    Google Scholar 

  • Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159:281–292

    Article  CAS  PubMed  Google Scholar 

  • Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of extended-infusion dosing strategy. Clin Infect Dis 44:357–363

    Article  CAS  PubMed  Google Scholar 

  • Lorente L, Jimenez A, Martin MM, Irbarren JL, Jimenez JJ, Mora ML (2009) Clinical cure of ventilator-associated pneumonia treated with piperacillin-tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 333:464–468

    Article  Google Scholar 

  • Lorian V, Zak O, Sutter J, Bruecher C (1985) Staphylococci in vitro and in vivo. Diagn Microbiol Infect Dis 3:433–444

    Article  CAS  PubMed  Google Scholar 

  • Louie A, Heine HS, Kim K, Brown DL, Van Scoy B, Liu W, Kinzig-Shippers M, Sorgel F, Drusano GL (2008) Use of an in vitro pharmacodynamic model to devise a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 52:2486–2496

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL (2010) Impact of different carbapenems and regimen of administration on resistance emergence for three isogenic Pseudomonas strains with differing mechanisms of resistance. Antimicrob Agents Chemother 54:2638–2645

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Maglio D, Nicolau DP, Nightingale CH (2003) Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am 17:563–577

    Article  PubMed  Google Scholar 

  • Maglio D, Ong C, Benevicius MA, Geng Q, Nightingale CH, Nicolau DP (2004) Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-betalactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 48:1941–1947

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mandell LA, Wunderlink RG, Anzuento A, Bartlett JG, Campbell D, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72

    Article  CAS  PubMed  Google Scholar 

  • McDonald PJ, Craig WA, Kunin CM (1977) Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 135:217–223

    Article  CAS  PubMed  Google Scholar 

  • McDonald PJ, Wetherall BL, Pruul H (1981) Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 3:38–44

    Article  CAS  PubMed  Google Scholar 

  • Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycosides therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93–99

    Article  CAS  PubMed  Google Scholar 

  • Mouton JW, van Ogtrop ML, Andes D, Craig WA (1999) Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 42:2473–2478

    Google Scholar 

  • Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH (2000) Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 44:1291–1295

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Oshida T, Onta T, Nakimishi T et al (1990) Activity of sub-minimal inhibitory concentrations of aspoxicillin in prolonging the postantibiotic effect against Staphylococcus aureus. J Antimicrob Chemother 26:29–38

    Article  CAS  PubMed  Google Scholar 

  • Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP (2011) Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrob Agents Chemother 55:1671–1683

    Article  Google Scholar 

  • Roberts JA, Webb S, Paterson D, Ho KM, Lipman J (2009) A systematic review of clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37:2071–2078

    Article  CAS  PubMed  Google Scholar 

  • Roberts JA, Kirkpatrick CM, Lipman J (2011) Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 66:227–231

    Article  CAS  PubMed  Google Scholar 

  • Rolinson GN (1973) Plasma concentrations of penicillin in relations to the antimicrobial effect. In: Davis DS, Pritchard BNC (eds) Biological effects of drugs in relation to the plasma concentration. University Park Press, Baltimore, MD, pp 183–189

    Google Scholar 

  • Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganiats TG, Gelzer A, Mamilos D, Haydon RC Jr, Hudgins PA, Jones S, Krouse HJ, Lee LH, Mahoney MC, Marple BF, Mitchell CJ, Nathan R, Shiffman RN, Smith TL, Witsell DL (2007) Clinical practice guidelines: adult sinusitis. Otolaryngol Head Neck Surg 137(Suppl 3):S1–S31

    Article  PubMed  Google Scholar 

  • Rybak MJ (2006) The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42:S35–S39

    Article  CAS  PubMed  Google Scholar 

  • Rybak MJ, Lomaestro BM, Rotschafer JC, Mollering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the IDSA, the ASH-SP, and the SIDP. Clin Infect Dis 49:325–327

    Article  PubMed  Google Scholar 

  • Shimizu K, Totsuka T, Watanabe T et al (1989) In vivo postantibiotic effects (PAE) of antimicrobials in neutropenic, normal and granulocytic mice. In: Proceeding and abstracts of the 29th interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology, Washington, DC, Abstract 939, p 258

    Google Scholar 

  • Stearne LE, Goessens WH, Mouton JW, Gyssens IC (2007) Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection. Antimicrob Agents Chemother 51:3605–3611

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tam VH, Louie A, Deziel MR, Liu W, Drusano GL (2007a) The relationship between quinolone exposures and resistance amplification is characterized by a inverted U; a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51:744–747

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tam VH, Schilling AN, Poole K, Nikolaou M (2007b) Mathematical modeling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 60:1302–1309

    Article  CAS  PubMed  Google Scholar 

  • Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheung A, Ballow CH, Schentag JJ (1998) Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42:521–527

    CAS  PubMed Central  PubMed  Google Scholar 

  • Turnidge J (2003) Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17:503–528

    Article  PubMed  Google Scholar 

  • Yost RJ, Cappelletty DM, RECEIPT Study Group (2011) The retrospective cohort of extended- infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 31:767–775

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Disease, University of Wisconsin School of Medicine and Public Health, MFCB-5th Floor, 1685 Highland Avenue, Madison, WI, 53705-2281, USA

    William A. Craig M.D.

Authors
  1. William A. Craig M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William A. Craig M.D. .

Editor information

Editors and Affiliations

  1. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

    Alexander A. Vinks

  2. Dept. Pharmaceutics, University of Florida, Gainesville College of Pharmacy, Gainesville, Florida, USA

    Hartmut Derendorf

  3. Dept. of Medical Microbiology, Radboudumc, Radboud University Nijmegen, Nijmegen, The Netherlands

    Johan W. Mouton

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Craig, W.A. (2014). Introduction to Pharmacodynamics. In: Vinks, A., Derendorf, H., Mouton, J. (eds) Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75613-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75613-4_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-75612-7

  • Online ISBN: 978-0-387-75613-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation